Processa Pharmaceuticals, Inc.

PCSA Nasdaq SEC CIK 1533743
Follow Processa Pharmaceuticals Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Net income −$183.2M −5229% vs same quarter last year
EPS, diluted −$61.58 −3302.2% vs same quarter last year
Operating cash flow −$5.2M −48.5% vs same quarter last year
Operating income −$184.1M −5177.4% vs same quarter last year
Net income by quarter
−$2.7M
−$2.8M
−$3.9M
−$3.4M
−$3.4M
−$3.4M
−$3.3M
−$183.2M
Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income15 fiscal years
  • Revenue
  • Net income
−$30M−$20M−$10M$0$10MFY11FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearRevenueNet income
FY25-−$13.6M
FY24-−$11.9M
FY23-−$11.1M
FY22$0−$27.4M
FY21$0−$11.4M
FY20-−$14.4M
FY19-−$3.4M
FY18-−$3.8M
FY17-−$1.9M
FY16$5K−$1.9M
FY15$113.4K−$3.4M
FY14$107.2K−$4.5M
FY13$312.5K−$3.1M
FY12$192.1K−$2.4M
FY11--
MarginsShare of revenue
  • Gross margin
  • Net margin
−40000%−30000%−20000%−10000%0%10000%FY11FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearGross marginNet margin
FY25--
FY24--
FY23--
FY22--
FY21--
FY20--
FY19--
FY18--
FY17--
FY16100%−38341.3%
FY15−11%−2957.2%
FY1437.7%−4220.7%
FY1339.8%−982%
FY1230.6%−1270.2%
FY11--
Free cash flowOperating cash flow minus capital expenditure
−$15M−$10M−$5M$0FY11FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearFree cash flow
FY25-
FY24−$11.2M
FY23−$8.1M
FY22-
FY21-
FY20-
FY19-
FY18-
FY17−$1.7M
FY16−$2.2M
FY15−$873.3K
FY14−$2.7M
FY13−$2.6M
FY12−$2.2M
FY11-
Net margin vs the sectorMedian of Healthcare companies filing with the SEC
  • Processa Pharmaceuticals
  • Healthcare median
−40000%−30000%−20000%−10000%0%FY11FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearProcessa PharmaceuticalsHealthcare median
FY25-−30.6%
FY24-−47%
FY23-−58%
FY22-−80.4%
FY21-−71.8%
FY20-−62.2%
FY19-−46.2%
FY18-−49.6%
FY17-−45.9%
FY16−38341.3%−36%
FY15−2957.2%−37.8%
FY14−4220.7%−35.5%
FY13−982%−37.1%
FY12−1270.2%−29.1%
FY11-−27.9%